美沙拉嗪联合益生菌治疗炎症性肠病的疗效分析

Analysis of the efficacy of mesalazine combined with probiotics in the treatment of inflammatory bowel disease

目的探究美沙拉嗪联合益生菌治疗炎症性肠病的临床疗效。方法100例炎症性肠病患者为研究对象,依据信封法将患者分为实验组与常规组,各50例。常规组使用美沙拉嗪单一用药治疗,实验组使用美沙拉嗪联合益生菌治疗。对比两组治疗效果、不良反应发生情况、治疗前后血清炎症因子水平、症状改善时间。结果实验组治疗总有效率98.0%高于常规组的80.0%,差异有统计学意义(P<0.05)。实验组不良反应发生率2.0%低于常规组的18.0%,差异有统计学意义(P<0.05)。治疗后,实验组患者肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平分别为(11.2±1.3)、(22.2±5.1)、(5.6±1.7)pg/ml,均低于常规组的(26.7±6.6)、(61.7±9.9)、(13.3±3.5)pg/ml,差异均有统计学意义(P<0.05)。实验组腹泻、腹痛、脓血便、里急后重改善时间分别为(6.2±0.4)、(3.9±0.6)、(5.9±0.7)、(6.9±0.2)d,均短于常规组的(7.6±0.3)、(6.8±0.8)、(7.0±1.3)、(9.8±0.3)d,差异均有统计学意义(P<0.05)。结论美沙拉嗪联合益生菌治疗炎症性肠病的疗效理想,值得推广使用。

Objective To investigate the clinical efficacy of mesalazine combined with probiotics in the treatment of inflammatory bowel disease.Methods A total of 100 patients with inflammatory bowel disease were studied,and the patients were divided into experimental group and conventional group based on the envelope method,with 50 cases in each group.The conventional group was treated with mesalazine monotherapy,and the experimental group was treated with mesalazine and probiotics.The therapeutic effects,occurrence of adverse reactions,serum inflammatory factor levels before and after treatment,and time to symptom improvement were compared between the two groups.Results The total effective rate of treatment in the experimental group was 98.0%,which was higher than 80.0%in the conventional group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 2.0%,which was lower than 18.0%in the conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and high-sensitivity C-reactive protein(hs-CRP)in the experimental group were(11.2±1.3),(22.2±5.1),and(5.6±1.7)pg/ml,which were lower than(26.7±6.6),(61.7±9.9),and(13.3±3.5)pg/ml in the conventional group,and the differences were statistically significant(P<0.05).The time to improvement of diarrhea,abdominal pain,purulent and bloody stools and tenesmus in the experimental group were(6.2±0.4),(3.9±0.6),(5.9±0.7)and(6.9±0.2)d,which were shorter than(7.6±0.3),(6.8±0.8),(7.0±1.3)and(9.8±0.3)d in the conventional group,and the differences were all statistically significant(P<0.05).Conclusion Mesalazine combined with probiotics has an ideal therapeutic effect on inflammatory bowel disease,which is worthy of promotion and application.